tiprankstipranks
Advertisement
Advertisement
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in MS Imaging Study
PremiumTipRanks NewswireQuantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in MS Imaging Study
18d ago
Quantum BioPharma Hits Midpoint in MGH Imaging Study as Lucid-MS Advances Toward Phase 2
Premium
Company Announcements
Quantum BioPharma Hits Midpoint in MGH Imaging Study as Lucid-MS Advances Toward Phase 2
19d ago
Quantum Group, Massachusetts General Hospital study halfway enrolled
Premium
The Fly
Quantum Group, Massachusetts General Hospital study halfway enrolled
19d ago
Quantum BioPharma Files FDA IND for Phase 2 Trial of Lucid-MS in Multiple Sclerosis
PremiumCompany AnnouncementsQuantum BioPharma Files FDA IND for Phase 2 Trial of Lucid-MS in Multiple Sclerosis
2M ago
Quantum BioPharma submits Lucid-21-302 new drug application to the FDA
Premium
The Fly
Quantum BioPharma submits Lucid-21-302 new drug application to the FDA
2M ago
Quantum BioPharma Taps Allucent for Phase 2 Trial of Novel MS Drug Lucid-MS
Premium
Company Announcements
Quantum BioPharma Taps Allucent for Phase 2 Trial of Novel MS Drug Lucid-MS
2M ago
Is QNTM a Buy, Before Earnings?
PremiumPre-EarningsIs QNTM a Buy, Before Earnings?
2M ago
Quantum BioPharma Wins Peer-Reviewed Validation for Unbuzzd Alcohol-Relief Supplement
Premium
Company Announcements
Quantum BioPharma Wins Peer-Reviewed Validation for Unbuzzd Alcohol-Relief Supplement
2M ago
Quantum BioPharma Raises C$3.75 Million and Converts Debt in Capital Restructuring Push
Premium
Company Announcements
Quantum BioPharma Raises C$3.75 Million and Converts Debt in Capital Restructuring Push
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100